NanoBio Corporation Receives $6 Million to Develop an Intranasal Vaccine for Respiratory Syncytial Virus (RSV)

ANN ARBOR, Mich.--(BUSINESS WIRE)--NanoBio Corporation announced today that it has received a $6M grant from the Bill & Melinda Gates Foundation to support the development of a safe and effective intranasal vaccine for Respiratory Syncytial Virus (RSV).

MORE ON THIS TOPIC